Maridebart cafraglutide
Maridebart cafraglutide is not a peptide. It is indexed alongside Incretin receptor agonists because it appears in the same research literature and the same search demand; no statement on this site describes it as a peptide.
Identity
| Field | Value |
|---|---|
| Classification | Not a peptide |
| Primary class | Incretin receptor agonists |
| CAS registry number | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| PubChem CID | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Molecular weight | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Maridebart cafraglutide, known as MariTide and by the code AMG 133, is an antibody-peptide conjugate rather than a peptide: a 2026 Journal of Medicinal Chemistry paper reports its discovery as a glucose-dependent insulinotropic polypeptide receptor antagonist combined with glucagon-like peptide 1 receptor agonism, and a 2026 Antibody Therapeutics paper discusses the design and rationale of antibody-peptide conjugates with it as the principal case. PubChem returned no compound record for the name.
A 2024 Nature Reviews Endocrinology item reports phase I results for AMG 133, and a 2025 New England Journal of Medicine paper reports a phase 2 trial of once-monthly administration in obesity, with correspondence and a reply published in the same journal later in 2025.
[2, 3, 4, 5, 6, 7]Reported mechanism
An antibody-peptide conjugate described in the retrieved records as a GIP receptor antagonist and GLP-1 receptor agonist.
[2]Stated in the title of the cited 2026 Journal of Medicinal Chemistry paper.
Targets named in the cited records: GLP-1 receptor, GIP receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[1]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Maridebart cafraglutide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- MariTide
- AMG 133
- AMG133
Where this page sits
Research records
Cited research records for Maridebart cafraglutide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Tirzepatide — Incretin receptor agonists
- Retatrutide — Incretin receptor agonists
Named targets in the cited records
Class page: Incretin receptor agonists. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Maridebart cafraglutide?
Maridebart cafraglutide, known as MariTide and by the code AMG 133, is an antibody-peptide conjugate rather than a peptide: a 2026 Journal of Medicinal Chemistry paper reports its discovery as a glucose-dependent insulinotropic polypeptide receptor antagonist combined with glucagon-like peptide 1 receptor agonism, and a 2026 Antibody Therapeutics paper discusses the design and rationale of antibody-peptide conjugates with it as the principal case. PubChem returned no compound record for the name.
Which class is Maridebart cafraglutide indexed under?
Maridebart cafraglutide is indexed under Incretin receptor agonists. Incretin receptor agonists are synthetic peptides that bind one or more of the incretin and glucagon family receptors, principally the glucagon-like peptide-1 receptor.
What does the FDA application register show for Maridebart cafraglutide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:maritide
- Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity. Journal of medicinal chemistry (2026). pmid:41941715
- Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications. Antibody therapeutics (2026). pmid:42592044
- Phase I results for AMG 133. Nature reviews. Endocrinology (2024). pmid:38388678
- Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. The New England journal of medicine (2025). pmid:40549887
- Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. The New England journal of medicine (2025). pmid:41337722
- Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. Reply. The New England journal of medicine (2025). pmid:41337724
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.